| 期 |
栏目 |
标题 |
文件 |
| 卷 12, 编号 1 (2020) |
Articles |
The relationship between the concentration of fibroblast growth factor-23 and central hemodynamics in patients with chronic kidney disease |
|
| 卷 12, 编号 1 (2020) |
Articles |
Membranous glomerulonephritis: a modern view of the problem and treatment options |
|
| 卷 11, 编号 3 (2019) |
Articles |
The possibilities of therapeutic intervention and prevention of cerebrovascular complications in atrial fibrillation in patients on program hemodialysis |
|
| 卷 12, 编号 3 (2020) |
Articles |
Renal function and cytokine profile changes with COVID-19 |
|
| 卷 12, 编号 3 (2020) |
Articles |
Ezetimibe in chronic kidney disease: an effect on the risk of developing cardiovascular and cerebral complications |
|
| 卷 13, 编号 3 (2021) |
Articles |
Homocystein and folic acid in chronic kidney disease: clinical and predictive significance |
|
| 卷 13, 编号 3 (2021) |
Articles |
Membranose glomerulonephritis in the practice of a therapist |
|
| 卷 14, 编号 1 (2022) |
Articles |
Clinical value of erythrocitary indices in chronic glomerulonephritis |
|
| 卷 14, 编号 3 (2022) |
Articles |
Prevalence of risk factors for cerebrovascular diseases in patients with end-stage renal disease |
|
| 卷 15, 编号 1 (2023) |
Original Articles |
Clinical and functional characteristics of mineral and bone disorders in chronic kidney disease |
|
| 卷 15, 编号 2 (2023) |
Literature Reviews |
Thrombosis and embolism in patients with chronic kidney disease |
|
| 卷 15, 编号 3 (2023) |
Literature Reviews |
Acute tubulointerstitial nephritis of medicinal etiology: the focus is on antibacterial drugs |
|
| 卷 15, 编号 4 (2023) |
Literature Reviews |
Post-contrast acute kidney injury: definition, prevalence and risk factors |
|
